Nektar Therapeutics

Pearl Therapeutics, Inc.

Abbott Laboratories Corporation

Aridis Pharmaceuticals

Novartis Ag

Inhale Therapeutic Systems, Inc.

Abbvie Inc.

Novartis Pharma Ag

David Lechuga-Ballesteros

Reinhard Vehring

Mei-chang Kuo

Sarvajna Kumar Dwivedi

Rodger F Henry

Adrian Edward Smith

Sanjay R Chemburkar

Daniel A Dickman

James J Fort

Michael Steven Hartman

William Porter

Vidya B Joshi

Yuping Niu

Vu Truong-Le

Danforth Miller

Satoshi Ohtake

Luisa Yee

Tacey Viegas

Russell E Martin

Binh Pham

Hema Gursahani

Chester Leach

Yuan Song

Atul Saxena

John S Patton

Thomas E Tarara

Linda C Foster

Michael A Eldon

Kirsten M Cabot

C Simone Jude-Fishburn

David B Bennett

Herman E Snyder

Keith Washco

Sarma Duddu

Theresa D Sweeney

Richard Malcolmson

Srinivas Palakodaty

Alan Kugler

Trixie Tan

Jason H Speck

Sarvajna Jumar Dwivedi

Trixie K Tan

James Ivey

Ali Kazmi

Christopher Frantz

C Simone Fishburn

Binh V Pham

Russell Martin

Methods and systems for the preparation of conditioned micronized active agents. Additionally, methods and systems for in-process conditioning of micronized active agent particles and compositions comprising conditioned micronized materials.

Methods and systems for conditioning of particulate crystalline materials

Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchioalveolar lavage followed by assaying residual lung material.

Chemically modified small molecules

A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such asspecies,as well as those caused by, and multidrug resistant, using a formulation containing gallium (III), in a pharmaceutically acceptable salt or complex thereof.

Gallium formulation for the treatment and prevention of infectious diseases

Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.

Compositions, methods and systems for respiratory delivery of two or more active agents

New crystalline forms of lopinavir are disclosed.

Crystalline pharmaceutical

Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents

A method of preparing a pharmaceutical formulation comprises providing a solution comprising a first solvent, a second solvent, an active agent, and an excipient. The second solvent is less polar than the first solvent and the excipient is more soluble in water than the active agent. The first and second solvents are removed from the solution to produce particles comprising the active agent and the excipient. In one version, the excipient comprises an amino acid and/or a phospholipid. A pharmaceutical formulation made by a version of the invention comprises particles comprising an active agent and an excipient which at least partially encapsulates the active agent, wherein the excipient is more soluble in water than the active agent.

Pharmaceutical formulation comprising a water-insoluble active agent

The present invention provides a highly dispersible formulation comprising an active agent and a dipeptide or tripeptide comprising at least two leucyl residues. The composition of the invention possesses superior aerosol properties and is thus preferred for aerosolized administration to the lung. Also provided are a method for (i) increasing the dispersibility of an active-agent containing formulation for administration to the lung, and (ii) delivery of the composition to the lungs of a subject.

Compositions comprising an active agent

This invention provides formulations and methods for stabilizing viruses in liquid and dried formulations. In particular, formulations are provided including Zn+ cations that stabilize the viability of Rotaviruses. Methods of vaccination include neutralization of gastric contents and administration of the vaccine formulations of the invention.

Formulations for preservation of rotavirus

Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.

Growing community of inventors

San Jose, CA, United States of America

David Lechuga-Ballesteros